marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Rocket Pharmaceuticals Balance Sheet 2011-2024 | RCKT
Annual Balance Sheet Rocket Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-35.6 M | -120 M | -214 M | -263 M | -21.6 M | 24.5 M | -7.88 M | 116 M | -80 M | 3.54 M | -5.99 M | 1.34 M | - |
Long Term Debt |
19.4 M | 19.3 M | 19.1 M | 35.1 M | 45 M | 41.4 M | 49.5 M | 49 M | - | 2.55 M | 5.4 M | - | - |
Long Term Debt Current |
925 K | 773 K | 863 K | 626 K | 957 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 46.5 M | 41.9 M | 49.9 M | 49.3 M | 367 K | 3.06 M | 7.31 M | 24 K | - |
Total Current Liabilities |
48.5 M | 39.2 M | 22.2 M | 32.6 M | 18.3 M | 15.4 M | 4.07 M | 7.21 M | 4.14 M | - | - | - | - |
Total Liabilities |
73.8 M | 62.1 M | 42.3 M | 87.3 M | 64.8 M | 57.3 M | 54 M | 56.5 M | 4.51 M | 10.3 M | 10.5 M | 3.79 M | - |
Deferred Revenue |
- | - | - | - | 562 K | 534 K | 506 K | 478 K | 450 K | 421 K | 394 K | 367 K | - |
Retained Earnings |
-959 M | -714 M | -492 M | -323 M | -183 M | -106 M | -268 M | -239 M | -196 M | -128 M | -119 M | -111 M | - |
Total Assets |
566 M | 552 M | 497 M | 591 M | 372 M | 251 M | 102 M | 130 M | 113 M | 5.52 M | 12.9 M | 1.42 M | - |
Cash and Cash Equivalents |
55.9 M | 141 M | 234 M | 299 M | 185 M | 111 M | 78.7 M | 29.8 M | 80 M | 3.62 M | - | - | - |
Book Value |
493 M | 490 M | 455 M | 504 M | 307 M | 194 M | 47.8 M | 73.2 M | 109 M | -4.76 M | 2.34 M | -2.37 M | - |
Total Shareholders Equity |
493 M | 490 M | 455 M | 504 M | 307 M | 194 M | 15.5 M | 73.2 M | 109 M | -51.6 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Rocket Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19.4 M | 19.4 M | 19.4 M | 19.4 M | 19.3 M | 19.3 M | 200 K | 19.3 M | 19.2 M | 19.2 M | 19.2 M | 19.1 M | 19.1 M | 19.1 M | 19 M | 19 M | 19 M | 19 M | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
63.9 M | 61.8 M | 57.9 M | 73.8 M | 57.7 M | 58.8 M | 55.9 M | 62.1 M | 50 M | 44.2 M | 42.5 M | 42.3 M | 44.6 M | 45.7 M | 96.5 M | 87.3 M | 87.3 M | 87.3 M | 87.3 M | 64.8 M | 64.8 M | 64.8 M | 64.8 M | 57.3 M | 57.3 M | 57.3 M | 57.3 M | 4.63 M | 4.63 M | 4.63 M | 4.63 M | 56.5 M | 56.5 M | 56.5 M | 56.5 M | 4.51 M | 4.51 M | 4.51 M | 4.51 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.16 B | -1.09 B | -1.02 B | -959 M | -900 M | -838 M | -772 M | -714 M | -647 M | -589 M | -535 M | -492 M | -448 M | -398 M | -363 M | -323 M | -323 M | -323 M | -323 M | -183 M | -183 M | -183 M | -183 M | -106 M | -106 M | -106 M | -106 M | -31.4 M | -31.4 M | -31.4 M | -31.4 M | -239 M | -239 M | -239 M | -239 M | -196 M | -196 M | -196 M | -196 M | -128 M | -128 M | -128 M | -128 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
394 M | 446 M | 499 M | 566 M | 599 M | 462 M | 515 M | 552 M | 417 M | 432 M | 460 M | 497 M | 530 M | 535 M | 576 M | 591 M | 591 M | 591 M | 591 M | 372 M | 372 M | 372 M | 372 M | 251 M | 251 M | 251 M | 251 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 130 M | 130 M | 130 M | 130 M | 113 M | 113 M | 113 M | 113 M | 5.52 M | 5.52 M | 5.52 M | 5.52 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
65.6 M | 38.6 M | 35.3 M | 55.9 M | 227 M | 46.4 M | 65.9 M | 141 M | 198 M | 189 M | 132 M | 233 M | 247 M | 266 M | 253 M | 299 M | 297 M | 297 M | 297 M | 185 M | 185 M | 185 M | 185 M | 111 M | 111 M | 111 M | 111 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 80 M | 80 M | 80 M | 80 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 12.8 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
330 M | 385 M | 442 M | 493 M | 541 M | 403 M | 459 M | 490 M | 367 M | 388 M | 418 M | 455 M | 486 M | 489 M | 480 M | 504 M | 504 M | 504 M | 504 M | 307 M | 307 M | 307 M | 307 M | 194 M | 194 M | 194 M | 194 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 109 M | 109 M | 109 M | 109 M | -4.76 M | -4.76 M | -4.76 M | -4.76 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
330 M | 385 M | 442 M | 493 M | 541 M | 403 M | 459 M | 490 M | 367 M | 388 M | 418 M | 455 M | 486 M | 489 M | 480 M | 504 M | 504 M | 504 M | 504 M | 307 M | 307 M | 307 M | 307 M | 194 M | 194 M | 194 M | 194 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 8.37 M | 73.2 M | 73.2 M | 73.2 M | 15.5 M | 109 M | 109 M | 109 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | -38.9 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency